The tumor suppressor role of CTCF

Journal of Cellular Physiology

Volumn 227, Issue 2, 2012, Pages 479-492

  Fiorentino, Francesco Paolo ^a   Giordano, Antonio ^a,b  

^a Temple University   (United States)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; HISTONE DEACETYLASE 3; RETINOBLASTOMA PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR CTCF; TRICHOSTATIN A; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; BREAST CANCER; CANCER CELL CULTURE; CD4+ T LYMPHOCYTE; CELL AGING; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL TYPE; COLON CANCER; DNA BINDING; DNA METHYLATION; EPIGENETICS; FIBROBLAST; GENE LOCUS; GLIOMA CELL; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA CELL; MOLECULAR BIOLOGY; MYELOID DENDRITIC CELL; ONCOGENE C MYC; OSTEOSARCOMA; OVARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; TELOMERE; TESTIS TUMOR; TRANSCRIPTION REGULATION; TUMOR CELL; UTERINE CERVIX CANCER;

DNA; GENE EXPRESSION REGULATION; HUMANS; PROTEIN BINDING; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 82155188552     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22780     Document Type: Review

References (170)

1. Aïssani B, Bernardi G. 1991. CpG islands: Features and distribution in the genomes of vertebrates. Gene 106: 173-183.
2. Albert I, Mavrich TN, Tomsho LP, Qi J, Zanton SJ, Schuster SC, Pugh. BF. 2007. Translational and rotational settings of H2A Z. Nucleosomes across the Saccharomyces cerevisiae genome. Nature 446: 572-576.
3. Albihn A, Johnsen JI, Henriksson MA. 2010. MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res 107: 163-224.
4. Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D, Barrett JC. 1996. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci USA 93: 13742-13747.
5. Archer TK, Cordingley MG, Wolford RG, Hager GL. 1991. Transcription factor access is mediated by accurately positioned nucleosomes on the mouse mammary tumor virus promoter. Mol Cell Biol 11: 688-698.
6. Arnold R, Mäueler W, Bassili G, Lutz M, Burke L, Epplen TJ, Renkawitz R. 2000. The insulator protein CTCF represses transcription on binding to the (gt) (22) (ga) (15) microsatellite in intron 2 of the HLA-DRB1 (*)0401 gene. Gene 253: 209-214.
7. Awad TA, Bigler J, Ulmer JE, Hu YJ, Moore JM, Lutz M, Neiman PE, Collins SJ, Renkawitz R, Lobanenkov VV, Filippova GN. 1999. Negative transcriptional regulation mediated by thyroid hormone response element 144 requires binding of the multivalent factor CTCF to a novel target DNA sequence. J Biol Chem 274: 27092-27098.
8. Baldi A, Esposito V, de Luca A, Howard CM, Mazzarella G, Baldi F, Caputi M, Giordano A. 1996. Differential expression of the retinoblastoma gene family members pRb/p105, p107, and pRb2/p130 in lung cancer. Clin Cancer Res 2: 1239-1245.
9. Baldi A, Esposito V, de Luca A, Fu Y, Meoli I, Giordano GG, Caputi M, Baldi F, Giordano A. 1997. Differential expression of Rb2/p130 and p107 in normal human tissues and in primary lung cancer. Clin Cancer Res 3: 1691-1697.
10. Baniahmad A, Steiner C, Köhne AC, Renkawitz R. 1990. Modular structure of a chicken lysozyme silencer: Involvement of an unusual thyroid hormone receptor binding site. Cell 61: 505-514.
11. Bao L, Zhou M, Cui. Y. 2008. CTCFBSDB: A CTCF-binding site database for characterization of vertebrate genomic insulators. Nucleic Acids Res 36: D83-D87.
12. Barski A, Cuddapah S, Cui K, Roh T, Schones DE, Wang Z, Wei G, Chepelev I, Zhao. K. 2007. High-resolution profiling of histone methylations in the human genome. Cell 129: 823-837.
13. Bell AC, West AG, Felsenfeld G. 1999. The protein CTCF is required for the enhancer blocking activity of vertebrate insulators. Cell 98: 387-396.
14. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA. 2008. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499-507.
15. Berger SL. 2007. The complex language of chromatin regulation during transcription. Nature 447: 407-412.
16. Boyle AP, Song L, Lee B, London D, Keefe D, Birney E, Iyer VR, Crawford GE, Furey TS. 2011. High-resolution genome-wide in vivo footprinting of diverse transcription factors in human cells. Genome Res 21: 456-464.
17. Bracken AP, Kleine-Kohlbrecher D, Dietrich N, Pasini D, Gargiulo G, Beekman C, Theilgaard-Mönch K, Minucci S, Porse BT, Marine J, Hansen KH, Helin K. 2007. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev 21: 525-530.
18. Burcin M, Arnold R, Lutz M, Kaiser B, Runge D, Lottspeich F, Filippova GN, Lobanenkov VV, Renkawitz R. 1997. Negative protein 1, which is required for function of the chicken lysozyme gene silencer in conjunction with hormone receptors, is identical to the multivalent zinc finger repressor CTCF. Mol Cell Biol 17: 1281-1288.
19. Burkhart DL, Ngai LK, Roake CM, Viatour P, Thangavel C, Ho VM, Knudsen ES. and J. Sage. 2010. Regulation of RB transcription in vivo by RB family members. Mol Cell Biol 30: 1729-1745.
20. Burkhart DL, Sage J. 2008. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 8: 671-682.
21. Cagle PT, el-Naggar AK, Xu HJ, Hu SX, Benedict WF. 1997. Differential retinoblastoma protein expression in neuroendocrine tumors of the lung. Potential diagnostic implications. Am J Pathol 150: 393-400.
22. Cánepa ET, Scassa ME, Ceruti JM, Marazita MC, Carcagno AL, Sirkin PF, Ogara MF. 2007. INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. TBMB 59: 419-426.
23. Chernukhin I, Shamsuddin S, Kang SY, Bergström R, Kwon Y, Yu W, Whitehead J, Mukhopadhyay R, Docquier F, Farrar D, Morrison I, Vigneron M, Wu S, Chiang C, Loukinov D, Lobanenkov V, Ohlsson R, Klenova E. 2007. CTCF interacts with and recruits the largest subunit of RNA polymerase II to CTCF target sites genome-wide. Mol Cell Biol 27: 1631-1648.
24. Chicas A, Wang X, Zhang C, Mccurrach M, Zhao Z, Mert O, Dickins RA, Narita M, Zhang M, Lowe. SW. 2010. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell 17: 376-387.
25. Choi J, Min NY, Park J, Kim JH, Park SH, Ko YJ, Kang Y, Moon YJ, Rhee S, Ham SW, Park AJ, Lee. K. 2010. TSA-induced DNMT1 down-regulation represses hTERT expression via recruiting CTCF into demethylated core promoter region of hTERT in HCT116. Biochem Biophys Res Commun 391: 449-454.
26. Choi JK, Kim. Y. 2009. Intrinsic variability of gene expression encoded in nucleosome positioning sequences. Nat Genet 41: 498-503.
27. Classon M, Dyson N. 2001. p107 and p130: Versatile proteins with interesting pockets. Exp Cell Res 264: 135-147.
28. Cong YS, Bacchetti S. 2000. Histone deacetylation is involved in the transcriptional repression of hTERT in normal human cells. J Biol Chem 275: 35665-35668.
29. Costello JF, Frühwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomäki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK, Plass C. 2000. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24: 132-138.
30. Crowe DL, Nguyen DC, Tsang KJ, Kyo. S. 2001. E2F-1 represses transcription of the human telomerase reverse transcriptase gene. Nucleic Acids Res 29: 2789-2794.
31. Cuddapah S, Jothi R, Schones DE, Roh T, Cui K, Zhao. K. 2009. Global analysis of the insulator binding protein CTCF in chromatin barrier regions reveals demarcation of active and repressive domains. Genome Res 19: 24-32.
32. Cukusić A, Vidacek NS, Sopta M, Rubelj I. 2008. Telomerase regulation at the crossroads of cell fate. Cytogenet Genome Res 122: 263-272.
33. D'arcy V, Pore N, Docquier F, Abdullaev ZK, Chernukhin I, Kita G, Rai S, Smart M, Farrar D, Pack S, Lobanenkov V, Klenova E. 2008. BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours. Br J Cancer 98: 571-579.
34. Dai Z, Dai X, Xiang Q, Feng J, Deng Y, Wang J. 2009. Insights into distinct regulatory modes of nucleosome positioning. BMC Genom 10: 602.
35. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li. F. 2006. The c-Myc target gene network. Semin Cancer Biol 16: 253-264.
36. Dannenberg JH, van Rossum A, Schuijff L, te Riele H. 2000. Ablation of the retinoblastoma gene family deregulates G (1) control causing immortalization and increased cell turnover under growth-restricting conditions. Genes Dev 14: 3051-3064.
37. Datta A, Nag A, Pan W, Hay N, Gartel AL, Colamonici O, Mori Y, Raychaudhuri P. 2004. Myc-ARF (alternate reading frame) interaction inhibits the functions of Myc. J Biol Chem 279: 36698-36707.
38. Delgado-Olguin P, Brand-Arzamendi K, Scott IC, Jungblut B, Stainier DY, Bruneau BG, Recillas-Targa F. 2011. CTCF promotes muscle differentiation by modulating the activity of myogenic regulatory factors. J Biol Chem 286: 12483-12494.
39. Di Fiore B, Palena A, Felsani A, Palitti F, Caruso M, Lavia P. 1999. Cytosine methylation transforms an E2F site in the retinoblastoma gene promoter into a binding site for the general repressor methylcytosine-binding protein 2 (MeCP2). Nucleic Acids Res 27: 2852-2859.
40. Docquier F, Farrar D, D'Arcy V, Chernukhin I, Robinson AF, Loukinov D, Vatolin S, Pack S, Mackay A, Harris RA, Dorricott H, O'Hare MJ, Lobanenkov V, Klenova E. 2005. Heightened expression of CTCF in breast cancer cells is associated with resistance to apoptosis. Cancer Res 65: 5112-5122.
41. Donohoe ME, Zhang L, Xu N, Shi Y, Lee. JT. 2007. Identification of a Ctcf cofactor, Yy1, for the X chromosome binary switch. Mol Cell 25: 43-56.
42. Ehrich M, Turner J, Gibbs P, Lipton L, Giovanneti M, Cantor C, van den Boom. D. 2008. Cytosine methylation profiling of cancer cell lines. Proc Natl Acad Sci USA 105: 4844-4849.
43. Engel N, Thorvaldsen JL, Bartolomei MS. 2006. CTCF binding sites promote transcription initiation and prevent DNA methylation on the maternal allele at the imprinted H19/Igf2 locus. Hum Mol Genet 15: 2945-2954.
44. Essien K, Vigneau S, Apreleva S, Singh L, Bartolomei M, Hannenhalli S. 2009. CTCF binding site classes exhibit distinct evolutionary, genomic, epigenomic and transcriptomic features. Genome Biol 10: R131.
45. Esteller M. 2005. Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol 45: 629-656.
46. Esteller M. 2007. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8: 286-298.
47. Farrar D, Rai S, Chernukhin I, Jagodic M, Ito Y, Yammine S, Ohlsson R, Murrell A, Klenova E. 2010. Mutational analysis of the poly (ADP-ribosyl)ation sites of the transcription factor CTCF provides an insight into the mechanism of its regulation by poly (ADP-ribosyl)ation. Mol Cell Biol 30: 1199-1216.
48. Feinberg AP, Tycko B. 2004. The history of cancer epigenetics. Nat Rev Cancer 4: 143-153.
49. Ferrari R, Pellegrini M, Horwitz GA, Xie W, Berk AJ, Kurdistani SK. 2008. Epigenetic reprogramming by adenovirus e1a. Science 321: 1086-1088.
50. Filippova GN, Fagerlie S, Klenova EM, Myers C, Dehner Y, Goodwin G, Neiman PE, Collins SJ, Lobanenkov VV. 1996. An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes. Mol Cell Biol 16: 2802-2813.
51. Filippova GN, Qi C, Ulmer JE, Moore JM, Ward MD, Hu YJ, Loukinov DI, Pugacheva EM, Klenova EM, Grundy PE, Feinberg AP, Cleton-Jansen A, Moerland EW, Cornelisse CJ, Suzuki H, Komiya A, Lindblom A, Dorion-Bonnet F, Neiman PE, Morse HC, Collins SJ, Lobanenkov VV. 2002. Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter tts DNA-binding specificity. Cancer Res 62: 48-52.
52. Fiorentino FP, Symonds CE, Macaluso M, Giordano A. 2009. Senescence and p130/Rbl2: A new beginning to the end. Cell Res 19: 1044-1051.
53. Fiorentino FP, Macaluso M, Miranda F, Montanari M, Russo A, Bagella L, Giordano A. 2011. CTCF and BORIS regulate Rb2/p130 gene transcription: A novel mechanism and a new paradigm for understanding the biology of lung cancer. Mol Cancer Res 9: 225-233.
54. Freytag SO. 1988. Enforced expression of the c-myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in G0/G. Mol Cell Biol 8: 1614-1624.
55. Fu Y, Sinha M, Peterson CL, Weng. Z. 2008. The insulator binding protein CTCF positions 20 nucleosomes around its binding sites across the human genome. PLoS Genet 4: e1000138.
56. Gandarillas A, Watt. FM. 1997. c-Myc promotes differentiation of human epidermal stem cells. Genes Dev 11: 2869-2882.
57. Gardiner-Garden M, Frommer M. 1987. CpG islands in vertebrate genomes. J Mol Biol 196: 261-282.
58. Gaszner M, Felsenfeld G. 2006. Insulators: Exploiting transcriptional and epigenetic mechanisms. Nat Rev Genet 7: 703-713.
59. Gil J, Peters G. 2006. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: All for one or one for all. Nat Rev Mol Cell Biol 7: 667-677.
60. Gombert WM, Farris SD, Rubio ED, Morey-Rosler KM, Schubach WH, Krumm A. 2003. The c-myc insulator element and matrix attachment regions define the c-myc chromosomal domain. Mol Cell Biol 23: 9338-9348.
61. Gombert WM, Krumm A. 2009. Targeted deletion of multiple CTCF-binding elements in the human C-MYC gene reveals a requirement for CTCF in C-MYC expression. PLoS ONE 4: e6109.
62. Guelen L, Pagie L, Brasset E, Meuleman W, Faza MB, Talhout W, Eussen BH, de Klein A, Wessels L, de Laat W, van Steensel B. 2008. Domain organization of human chromosomes revealed by mapping of nuclear lamina interactions. Nature 453: 948-951.
63. Harbour JW, Lai SL, Whang-Peng J, Gazdar AF, Minna JD, Kaye. FJ. 1988. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241: 353-357.
64. Haupt Y, Rowan S, Shaulian E, Vousden KH, Oren. M. 1995. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev 9: 2170-2183.
65. Heath H, Ribeiro de Almeida C, Sleutels F, Dingjan G, van de Nobelen S, Jonkers I, Ling K, Gribnau J, Renkawitz R, Grosveld F, Hendriks RW, Galjart N. 2008. CTCF regulates cell cycle progression of alphabeta T cells in the thymus. EMBO J 27: 2839-2850.
66. Heintzman N, Hon G, Hawkins R, Kheradpour P, Stark A, Harp L, Ye Z, Lee L, Stuart R, Ching C, Ching K, Antosiewicz-Bourget J, Liu H, Zhang X, Green R, Lobanenkov V, Stewart R, Thomson J, Crawford G, Kellis M, Ren. B. 2009. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 459: 108-112.
67. Helmbold H, Deppert W, Bohn. W. 2006. Regulation of cellular senescence by Rb2/p130. Oncogene 25: 5257-5262.
68. Helmbold H, Kömm N, Deppert W, Bohn. W. 2009. Rb2/p130 is the dominating pocket protein in the p53-p21 DNA damage response pathway leading to senescence. Oncogene 28: 3456-3467.
69. Hoffman B, Amanullah A, Shafarenko M, Liebermann DA. 2002. The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene 21: 3414-3421.
70. Hollstein M, Hainaut P. 2010. Massively regulated genes: The example of TP53. J Pathol 220: 164-173.
71. Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, Fischette MR, Adnani MT, Loukinov DI, Vatolin S, Risinger JI, Custer M, Chen GA, Zhao M, Nguyen DM, Barrett JC, Lobanenkov VV, Schrump DS. 2005. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res 65: 7763-7774.
72. Hou C, Zhao H, Tanimoto K, Dean. A. 2008. CTCF-dependent enhancer-blocking by alternative chromatin loop formation. Proc Natl Acad Sci USA 105: 20398-20403.
73. Hou M, Wang X, Popov N, Zhang A, Zhao X, Zhou R, Zetterberg A, Björkholm M, Henriksson M, Gruber A, Xu. D. 2002. The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells. Exp Cell Res 274: 25-34.
74. Ip SM, Huang TG, Yeung WS, Ngan. HY. 2001. pRb-expressing adenovirus Ad5-Rb attenuates the p53-induced apoptosis in cervical cancer cell lines. Eur J Cancer 37: 2475-2483.
75. Jayapal SR, Lee KL, Ji P, Kaldis P, Lim B, Lodish HF. 2010. Downregulation of MYC is essential for terminal erythroid maturation. J Biol Chem 285: 40252-40265.
76. Jothi R, Cuddapah S, Barski A, Cui K, Zhao. K. 2008. Genome-wide identification of in vivo protein-DNA binding sites from ChIP-Seq data. Nucleic Acids Res 36: 5221-5231.
77. Kanduri C, Pant V, Loukinov D, Pugacheva E, Qi CF, Wolffe A, Ohlsson R, Lobanenkov VV. 2000. Functional association of CTCF with the insulator upstream of the H19 gene is parent of origin-specific and methylation-sensitive. Curr Biol 10: 853-856.
78. Kanduri M, Kanduri C, Mariano P, Vostrov AA, Quitschke W, Lobanenkov V, Ohlsson R. 2002. Multiple nucleosome positioning sites regulate the CTCF-mediated insulator function of the H19 imprinting control region. Mol Cell Biol 22: 3339-3344.
79. Kapić A, Helmbold H, Reimer R, Klotzsche O, Deppert W, Bohn. W. 2006. Cooperation between p53 and p130 (Rb2) in induction of cellular senescence. Cell Death Differ 13: 324-334.
80. Khidr L, Chen. P. 2006. RB, the conductor that orchestrates life, death and differentiation. Oncogene 25: 5210-5219.
81. Kim TH, Abdullaev ZK, Smith AD, Ching KA, Loukinov DI, Green RD, Zhang MQ, Lobanenkov VV, Ren. B. 2007. Analysis of the vertebrate insulator protein CTCF-binding sites in the human genome. Cell 128: 1231-1245.
82. Kim WY, Sharpless NE. 2006. The regulation of INK4/ARF in cancer and aging. Cell 127: 265-275.
83. Kitchen NS, Schoenherr CJ. 2010. Sumoylation modulates a domain in CTCF that activates transcription and decondenses chromatin. J Cell Biochem 111: 665-675.
84. Klenova EM, Nicolas RH, Paterson HF, Carne AF, Heath CM, Goodwin GH, Neiman PE, Lobanenkov VV. 1993. CTCF, a conserved nuclear factor required for optimal transcriptional activity of the chicken c-myc gene, is an 11-Zn-finger protein differentially expressed in multiple forms. Mol Cell Biol 13: 7612-7624.
85. Klenova EM, Chernukhin IV, El-Kady A, Lee RE, Pugacheva EM, Loukinov DI, Goodwin GH, Delgado D, Filippova GN, León J, Morse HC, Neiman PE, Lobanenkov VV. 2001. Functional phosphorylation sites in the C-terminal region of the multivalent multifunctional transcriptional factor CTCF. Mol Cell Biol 21: 2221-2234.
86. Klenova EM, Morse HC, Ohlsson R, Lobanenkov VV. 2002. The novel BORIS+CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Semin Cancer Biol 12: 399-414.
87. Kotake Y, Cao R, Viatour P, Sage J, Zhang Y, Xiong Y. 2007. pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene. Genes Dev 21: 49-54.
88. Köhne AC, Baniahmad A, Renkawitz R. 1993. NeP1. A ubiquitous transcription factor synergizes with v-ERBA in transcriptional silencing. J Mol Biol 232: 747-755.
89. Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al-Regaiey K, Su L, Sharpless NE. 2004. Ink4a/Arf expression is a biomarker of aging. J Clin Invest 114: 1299-1307.
90. de La Rosa-Velázquez, IA, Rincón-Arano H, Benítez-Bribiesca L, Recillas-Targa F. 2007. Epigenetic regulation of the human retinoblastoma tumor suppressor gene promoter by CTCF. Cancer Res 67: 2577-2585.
91. Lai AY, Fatemi M, Dhasarathy A, Malone C, Sobol SE, Geigerman C, Jaye DL, Mav D, Shah R, Li L, Wade. PA. 2010. DNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas. J Exp Med 207: 1939-1950 .
92. Lefevre P, Witham J, Lacroix CE, Cockerill PN, Bonifer C. 2008. The LPS-induced transcriptional upregulation of the chicken lysozyme locus involves CTCF eviction and noncoding RNA transcription. Mol Cell 32: 129-139.
93. Li H, Collado M, Villasante A, Strati K, Ortega S, Cañamero M, Blasco MA, Serrano M. 2009. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 460: 1136-1139.
94. Li H, Wu. X. 2004. Histone deacetylase inhibitor, Trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells. Biochem Biophys Res Commun 324: 860-867.
95. Litovchick L, Sadasivam S, Florens L, Zhu X, Swanson SK, Velmurugan S, Chen R, Washburn MP, Liu XS, DeCaprio JA. 2007. Evolutionarily conserved multisubunit RBL2/p130 and E2F4 protein complex represses human cell cycle-dependent genes in quiescence. Mol Cell 26: 539-551.
96. Lobanenkov VV, Nicolas RH, Adler VV, Paterson H, Klenova EM, Polotskaja AV, Goodwin GH. 1990. A novel sequence-specific DNA binding protein which interacts with three regularly spaced direct repeats of the CCCTC-motif in the 5'-flanking sequence of the chicken c-myc gene. Oncogene 5: 1743-1753.
97. Loukinov DI, Pugacheva E, Vatolin S, Pack SD, Moon H, Chernukhin I, Mannan P, Larsson E, Kanduri C, Vostrov AA, Cui H, Niemitz EL, Rasko JEJ, Docquier FM, Kistler M, Breen JJ, Zhuang Z, Quitschke WW, Renkawitz R, Klenova EM, Feinberg AP, Ohlsson R, Morse HC, Lobanenkov VV. 2002. BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci USA 99: 6806-6811.
98. Lowe SW, Cepero E, Evan. G. 2004. Intrinsic tumour suppression. Nature 432: 307-315.
99. Lutz M, Burke LJ, Barreto G, Goeman F, Greb H, Arnold R, Schultheiss H, Brehm A, Kouzarides T, Lobanenkov V, Renkawitz R. 2000. Transcriptional repression by the insulator protein CTCF involves histone deacetylases. Nucleic Acids Res 28: 1707-1713.
100. Lutz M, Burke LJ, Lefevre P, Myers FA, Thorne AW, Crane-Robinson C, Bonifer C, Filippova GN, Lobanenkov V, Renkawitz R. 2003. Thyroid hormone-regulated enhancer blocking: Cooperation of CTCF and thyroid hormone receptor. EMBO J 22: 1579-1587.
101. MacPherson MJ, Beatty LG, Zhou W, Du M, Sadowski PD. 2009. The CTCF insulator protein is posttranslationally modified by SUMO. Mol Cell Biol 29: 714-725.
102. Majumder P, Gomez JA, Chadwick BP, Boss. JM. 2008. The insulator factor CTCF controls MHC class II gene expression and is required for the formation of long-distance chromatin interactions. J Exp Med 205: 785-798.
103. Martinez-Garcia E, Licht JD. 2010. Deregulation of H3K27 methylation in cancer. Nat Genet 42: 100-101.
104. Masutomi K, Yu EY, Khurts S, Ben-Porath I, Currier JL, Metz GB, Brooks MW, Kaneko S, Murakami S, DeCaprio JA, Weinberg RA, Stewart SA, Hahn. WC. 2003. Telomerase maintains telomere structure in normal human cells. Cell 114: 241-253.
105. Meeran SM, Patel SN, Tollefsbol TO. 2010. Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS ONE 5: e11457.
106. Moon H, Filippova G, Loukinov D, Pugacheva E, Chen Q, Smith ST, Munhall A, Grewe B, Bartkuhn M, Arnold R, Burke LJ, Renkawitz-Pohl R, Ohlsson R, Zhou J, Renkawitz R, Lobanenkov V. 2005. CTCF is conserved from Drosophila to humans and confers enhancer blocking of the Fab-8 insulator. EMBO Rep 6: 165-170.
107. Moss TJ, Wallrath LL. 2007. Connections between epigenetic gene silencing and human disease. Mutat Res 618: 163-174.
108. Mukhopadhyay R, Yu W, Whitehead J, Xu J, Lezcano M, Pack S, Kanduri C, Kanduri M, Ginjala V, Vostrov A, Quitschke W, Chernukhin I, Klenova E, Lobanenkov V, Ohlsson R. 2004. The binding sites for the chromatin insulator protein CTCF map to DNA methylation-free domains genome-wide. Genome Res 14: 1594-1602.
109. Muller M. 2009. Cellular senescence: molecular mechanisms, in vivo significance, and redox considerations. Antioxidants Redox Signaling 11: 59-98.
110. Mulligan G, Jacks T. 1998. The retinoblastoma gene family: Cousins with overlapping interests. Trend Genet 14: 223-229.
111. Narita M, Nũnez S, Heard E, Narita M, Lin AW, Hearn SA, Spector DL, Hannon GJ, Lowe. SW. 2003. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113: 703-716.
112. Narita M, Narita M, Krizhanovsky V, Nuñez S, Chicas A, Hearn SA, Myers MP, Lowe. SW. 2006. A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell 126: 503-514.
113. Ogino H, Nozaki T, Gunji A, Maeda M, Suzuki H, Ohta T, Murakami Y, Nakagama H, Sugimura T, Masutani M. 2007. Loss of Parp-1 affects gene expression profile in a genome-wide manner in ES cells and liver cells. BMC Genom 8: 41.
114. Ohlsson R, Renkawitz R, Lobanenkov V. 2001. CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. Trends Genet 17: 520-527.
115. Ohlsson R, Lobanenkov V, Klenova E. 2009. Does CTCF mediate between nuclear organization and gene expression. Bioessays 32: 37-50.
116. Ohtani N, Zebedee Z, Huot TJ, Stinson JA, Sugimoto M, Ohashi Y, Sharrocks AD, Peters G, Hara. E. 2001. Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature 409: 1067-1070.
117. Ozenne P, Eymin B, Brambilla E, Gazzeri S. 2010. The ARF tumor suppressor: Structure, functions and status in cancer. Int J Cancer 127: 2239-2247.
118. Parelho V, Hadjur S, Spivakov M, Leleu M, Sauer S, Gregson HC, Jarmuz A, Canzonetta C, Webster Z, Nesterova T, Cobb BS, Yokomori K, Dillon N, Aragon L, Fisher AG, Merkenschlager M. 2008. Cohesins functionally associate with CTCF on mammalian chromosome arms. Cell 132: 422-433.
119. Pérez-Juste G, García-Silva S, Aranda A. 2000. An element in the region responsible for premature termination of transcription mediates repression of c-myc gene expression by thyroid hormone in neuroblastoma cells. J Biol Chem 275: 1307-1314.
120. Phillips JE, Corces VG. 2009. CTCF: Master weaver of the genome. Cell 137: 1194-1211.
121. Qi C, Martensson A, Mattioli M, Dalla-Favera R, Lobanenkov VV, Morse HC. 2003. CTCF functions as a critical regulator of cell-cycle arrest and death after ligation of the B cell receptor on immature B cells. Proc Natl Acad Sci USA 100: 633-638.
122. Rasko JE, Klenova EM, Leon J, Filippova GN, Loukinov DI, Vatolin S, Robinson AF, Hu YJ, Ulmer J, Ward MD, Pugacheva EM, Neiman PE, Morse HC, Collins SJ, Lobanenkov VV. 2001. Cell growth inhibition by the multifunctional multivalent zinc-finger factor CTCF. Cancer Res 61: 6002-6007.
123. Rayman JB, Takahashi Y, Indjeian VB, Dannenberg J, Catchpole S, Watson RJ, te Riele H, Dynlacht BD. 2002. E2F mediates cell cycle-dependent transcriptional repression in vivo by recruitment of an HDAC1/mSin3B corepressor complex. Genes Dev 16: 933-947.
124. Renaud S, Loukinov D, Bosman FT, Lobanenkov V, Benhattar J. 2005. CTCF binds the proximal exonic region of hTERT and inhibits its transcription. Nucleic Acids Res 33: 6850-6860.
125. Renaud S, Loukinov D, Abdullaev Z, Guilleret I, Bosman FT, Lobanenkov V, Benhattar J. 2007. Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene. Nucleic Acids Res 35: 1245-1256.
126. Renaud S, Loukinov D, Alberti L, Vostrov A, Kwon Y, Bosman FT, Lobanenkov V, Benhattar J. 2010. BORIS/CTCFL-mediated transcriptional regulation of the hTERT telomerase gene in testicular and ovarian tumor cells. Nucleic Acids Res 39: 862-873.
127. Risinger JI, Chandramouli GVR, Maxwell GL, Custer M, Pack S, Loukinov D, Aprelikova O, Litzi T, Schrump DS, Murphy SK, Berchuck A, Lobanenkov V, Barrett JC. 2007. Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression. Clin Cancer Res 13: 1713-1719.
128. Rodriguez C, Borgel J, Court F, Cathala G, Forné T, Piette J. 2010. CTCF is a DNA methylation-sensitive positive regulator of the INK/ARF locus. Biochem Biophys Res Commun 392: 129-134.
129. Rubio ED. 2008. Supplemental Rubio.
130. Rubio ED, Reiss DJ, Welcsh PL, Disteche CM, Filippova GN, Baliga NS, Aebersold R, Ranish JA, Krumm A. 2008. CTCF physically links cohesin to chromatin. Proc Natl Acad Sci USA 105: 8309-8314.
131. Sage J, Mulligan GJ, Attardi LD, Miller A, Chen S, Williams B, Theodorou E, Jacks T. 2000. Targeted disruption of the three Rb-related genes leads to loss of G (1) control and immortalization. Genes Dev 14: 3037-3050.
132. Sakai T, Ohtani N, McGee TL, Robbins PD, Dryja TP. 1991. Oncogenic germ-line mutations in Sp1 and ATF sites in the human retinoblastoma gene. Nature 353: 83-86.
133. Selkirk JK, Merrick BA, Stackhouse BL, He. C. 1994. Multiple p53 protein isoforms and formation of oligomeric complexes with heat shock proteins Hsp70 and Hsp90 in the human mammary tumor, T47D, cell line. Appl Theor Electrophor 4: 11-18.
134. Sharpless NE. 2005. INK4a/ARF: A multifunctional tumor suppressor locus. Mutat Res 576: 22-38.
135. Sherr CJ, McCormick F. 2002. The RB and p53 pathways in cancer. Cancer Cell 2: 103-112.
136. Simon JA, Lange CA. 2008. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 647: 21-29.
137. Soshnikova N, Montavon T, Leleu M, Galjart N, Duboule D. 2010. Functional analysis of CTCF during mammalian limb development. Dev Cell 19: 819-830.
138. Soto-Reyes E, Recillas-Targa F. 2010. Epigenetic regulation of the human p53 gene promoter by the CTCF transcription factor in transformed cell lines. Oncogene 29: 2217-2227.
139. Spencer CA, Groudine M. 1991. Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res 56: 1-48.
140. Spivakov M, Fisher AG. 2007. Epigenetic signatures of stem-cell identity. Nat Rev Genet 8: 263-271.
141. Splinter E, Heath H, Kooren J, Palstra R, Klous P, Grosveld F, Galjart N, de Laat. W. 2006. CTCF mediates long-range chromatin looping and local histone modification in the beta-globin locus. Genes Dev 20: 2349-2354.
142. Stedman W, Kang H, Lin S, Kissil JL, Bartolomei MS, Lieberman PM. 2008. Cohesins localize with CTCF at the KSHV latency control region and at cellular c-myc and H19/Igf2 insulators. EMBO J 27: 654-666.
143. Takahashi Y, Rayman JB, Dynlacht BD. 2000. Analysis of promoter binding by the E2F and pRB families in vivo: Distinct E2F proteins mediate activation and repression. Genes Dev 14: 804-816.
144. Takakura M, Kyo S, Sowa Y, Wang Z, Yatabe N, Maida Y, Tanaka M, Inoue M. 2001. Telomerase activation by histone deacetylase inhibitor in normal cells. Nucleic Acids Res 29: 3006-3011.
145. Takakura M, Kyo S, Inoue M, Wright WE, Shay. JW. 2005. Function of AP-1 in transcription of the telomerase reverse transcriptase gene (TERT) in human and mouse cells. Mol Cell Biol 25: 8037-8043.
146. Tirosh I, Barkai N. 2008. Two strategies for gene regulation by promoter nucleosomes. Genome Res 18: 1084.
147. Torrano V, Chernukhin I, Docquier F, D'Arcy V, León J, Klenova E, Delgado MD. 2005. CTCF regulates growth and erythroid differentiation of human myeloid leukemia cells. J Biol Chem 280: 28152-28161.
148. Ulaner GA, Vu TH, Li T, Hu J, Yao X, Yang Y, Gorlick R, Meyers P, Healey J, Ladanyi M, Hoffman AR. 2003. Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Hum Mol Genet 12: 535-549.
149. van Riggelen J, Yetil A, Felsher DW. 2010. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer 10: 301-309.
150. Vatolin S, Abdullaev Z, Pack SD, Flanagan PT, Custer M, Loukinov DI, Pugacheva E, Hong JA, Morse H, Schrump DS, Risinger JI, Barrett JC, Lobanenkov VV. 2005. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res 65: 7751-7762.
151. Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature 408: 307-310.
152. Vostrov AA, Quitschke WW. 1997. The zinc finger protein CTCF binds to the APBbeta domain of the amyloid beta-protein precursor promoter. Evidence for a role in transcriptional activation. J Biol Chem 272: 33353-33359.
153. Vousden KH, Prives C. 2005. P53 and prognosis: New insights and further complexity. Cell 120: 7-10.
154. Wang S, Zhu. J. 2003. Evidence for a relief of repression mechanism for activation of the human telomerase reverse transcriptase promoter. J Biol Chem 278: 18842-18850.
155. Weinberg RA. 1995. The retinoblastoma protein and cell cycle control. Cell 81: 323-330.
156. Wierstra I, Alves J. 2008. The c-myc promoter: Still MysterY and challenge. Adv Cancer Res 99: 113-333.
157. Williams A, Flavell RA. 2008. The role of CTCF in regulating nuclear organization. J Exp Med 205: 747-750.
158. Witcher M, Emerson BM. 2009. Epigenetic silencing of the p16 (INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary. Mol Cell 34: 271-284.
159. Wong DJ, Segal E, Chang HY. 2008. Stemness, cancer and cancer stem cells. Cell Cycle 7: 3622-3624.
160. Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay. JW. 1996. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet 18: 173-179.
161. Wu P, Meng L, Wang H, Zhou J, Xu G, Wang S, Xi L, Chen G, Wang B, Zhu T, Lu Y, Ma. D. 2005. Role of hTERT in apoptosis of cervical cancer induced by histone deacetylase inhibitor. Biochem Biophys Res Commun 335: 36-44.
162. Xie X, Mikkelsen TS, Gnirke A, Lindblad-Toh K, Kellis M, Lander ES. 2007. Systematic discovery of regulatory motifs in conserved regions of the human genome, including thousands of CTCF insulator sites. Proc Natl Acad Sci USA 104: 7145-7150.
163. Xu D, Dwyer J, Li H, Duan W, Liu. J. 2008. Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc. J Biol Chem 283: 23567-23580.
164. Xu J, Huo D, Chen Y, Nwachukwu C, Collins C, Rowell J, Slamon D, Olopade O. 2009. CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors. Breast Cancer Res Treat 120: 593-601.
165. Xue Jun H., Gemma A, Hosoya Y, Matsuda K, Nara M, Hosomi Y, Okano T, Kurimoto F, Seike M, Takenaka K, Yoshimura A, Toyota M, Kudoh S. 2003. Reduced transcription of theRB2/p130 gene in human lung cancer. Mol Carcinog 38: 124-129.
166. Yoon H, Chan DW, Reynolds AB, Qin J, Wong. J. 2003. N-CoR mediates DNA methylation-dependent repression through a methyl CpG binding protein Kaiso. Mol Cell 12: 723-734.
167. Yu W, Ginjala V, Pant V, Chernukhin I, Whitehead J, Docquier F, Farrar D, Tavoosidana G, Mukhopadhyay R, Kanduri C, Oshimura M, Feinberg AP, Lobanenkov V, Klenova E, Ohlsson R. 2004. Poly (ADP-ribosyl)ation regulates CTCF-dependent chromatin insulation. Nat Genet 36: 1105-1110.
168. Zeller KI, Zhao X, Lee CWH, Chiu KP, Yao F, Yustein JT, Ooi HS, Orlov YL, Shahab A, Yong HC, Fu Y, Weng Z, Kuznetsov VA, Sung W, Ruan Y, Dang CV, Wei. C. 2006. Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci USA 103: 17834-17839.
169. Zhang Y, Xiong Y, Yarbrough WG. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734.
170. Zuckerman V, Wolyniec K, Sionov RV, Haupt S, Haupt Y. 2009. Tumour suppression by p53: The importance of apoptosis and cellular senescence. J Pathol 219: 3-15.